NASDAQ:JAGX Jaguar Animal Health Q1 2026 Earnings Report $2.98 +0.16 (+5.67%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$3.08 +0.10 (+3.19%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Jaguar Animal Health EPS ResultsActual EPSN/AConsensus EPS -$149.10Beat/MissN/AOne Year Ago EPSN/AJaguar Animal Health Revenue ResultsActual RevenueN/AExpected Revenue$4.21 millionBeat/MissN/AYoY Revenue GrowthN/AJaguar Animal Health Announcement DetailsQuarterQ1 2026Date5/14/2026TimeAfter Market ClosesConference Call DateThursday, May 14, 2026Conference Call Time4:15PM ETConference Call ResourcesEarnings HistoryCompany Profile Jaguar Animal Health Earnings HeadlinesJaguar Animal Health (JAGX) Projected to Post Quarterly Earnings on ThursdayMay 7 at 3:06 AM | americanbankingnews.comJaguar Animal Health (NASDAQ:JAGX) Rating Lowered to Strong Sell at Wall Street ZenMay 2, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 8 at 1:00 AM | InvestorPlace (Ad)Jaguar Animal Health (NASDAQ:JAGX) Stock Price Passes Below 200 Day Moving Average - What's Next?April 30, 2026 | americanbankingnews.comJaguar Health, Inc.: Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea in DogsApril 30, 2026 | finanznachrichten.deJaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for ...April 24, 2026 | usatoday.comSee More Jaguar Animal Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email. Email Address About Jaguar Animal HealthJaguar Animal Health (NASDAQ:JAGX) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments. Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding. The company is headquartered in East Windsor, New Jersey, and maintains a streamlined development organization designed to advance lead candidates from proof-of-concept through regulatory approvals and commercial launch. Among Jaguar’s key offerings is a proprietary probiotic formulation intended to reduce the incidence and severity of post-weaning diarrhea in piglets, which has received regulatory clearance in select markets. In parallel, the company is progressing a complementary feed-additive candidate for controlling necrotic enteritis in broiler chickens. Jaguar leverages in-house expertise in microbial therapeutics to optimize dosing regimens and demonstrate consistent performance under commercial farming conditions. To date, Jaguar Animal Health serves customers primarily in Latin America through strategic distribution partnerships, while preparing for broader market entry in North America. The company’s leadership team brings experience in veterinary development, regulatory affairs, and commercial operations, positioning Jaguar to address growing global demand for effective, antibiotic-reducing solutions in livestock production.View Jaguar Animal Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsSuper Micro Surges Over 20% as Margins Soar, Sales Fall ShortNuts and Bolts AI Play Gains Momentum: Astera Labs Targets RaisedAnheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Sony (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
